Hyperactive glial cells contribute to axonal pathologies in the spinal cord of Npc1 mutant mice

GLIA

Volumn 62, Issue 7, 2014, Pages 1024-1040

  Yan, Xin ^a   Yang, Fan ^a   Lukas, Jan ^a   Witt, Martin ^a   Wree, Andreas ^a   Rolfs, Arndt ^a   Luo, Jiankai ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

ApoE; Astrocytes; IL 1 ; Microglia; Neurodegeneration; Npc1; P38 MAPK

Indexed keywords

APOLIPOPROTEIN E; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 1BETA; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NPC1 PROTEIN; PROTEIN P10; PROTEIN P35; SYNAPTOPHYSIN; TAU PROTEIN; UNCLASSIFIED DRUG; CDK5 PROTEIN, MOUSE; CDK5R1 PROTEIN, MOUSE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; IL1B PROTEIN, MOUSE; MAPT PROTEIN, MOUSE; NPC1 PROTEIN, MOUSE; PHOSPHOTRANSFERASE; PROTEIN; SYP PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTRON MICROSCOPY; ENZYME ACTIVITY; FEMALE; GLIA CELL; GLIOSIS; IMMUNOREACTIVITY; MALE; MICROGLIA; MOUSE; NERVE DEGENERATION; NEUROFILAMENT; NONHUMAN; PERINATAL PERIOD; PICK PRESENILE DEMENTIA; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SPINAL CORD; TUMOR SPHEROID; UPREGULATION; VARICOSIS; AGE; ANIMAL; BAGG ALBINO MOUSE; DEGENERATIVE DISEASE; GENETICS; GLIA; INTERMEDIATE FILAMENT; KNOCKOUT MOUSE; METABOLISM; NERVE FIBER; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

AGE FACTORS; ANIMALS; APOLIPOPROTEINS E; ASTROCYTES; AXONS; CYCLIN-DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3; INTERLEUKIN-1BETA; INTERMEDIATE FILAMENTS; MICE, INBRED BALB C; MICE, KNOCKOUT; MICROGLIA; NEURODEGENERATIVE DISEASES; NEUROGLIA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PHOSPHOTRANSFERASES; PROTEINS; SPINAL CORD; SYNAPTOPHYSIN; TAU PROTEINS;

EID: 84900793631     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22659     Document Type: Article

References (68)

1. Bales KR, Verina T, Cummins DJ, Du Y, Dodel TC, Saura J, Fishman CE, Delong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM. 1999. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 96:15233-15238.
2. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM. 1997. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 17:263-264.
3. Barcelona PF, Ortiz SG, Chiabrando GA, Sanchez MC. 2011. alpha2-Macroglobulin induces glial fibrillary acidic protein expression mediated by low-density lipoprotein receptor-related protein 1 in Müller cells. Invest Ophthalmol Vis Sci 52:778-786.
4. Baudry M, Yao Y, Simmons D, Liu J, Bi X. 2003. Postnatal development of inflammation in a murine model of Niemann-Pick type C disease: Immunohistochemical observations of microglia and astroglia. Exp Neurol 184:887-903.
5. Bauer P, Knoblich R, Bauer C, Finckh U, Hufen A, Kropp J, Braun S, Kustermann-Kuhn B, Schmidt D, Harzer K, Rolfs A. 2002. NPC1: Complete genomic sequence, mutation analysis, and characterization of haplotypes. Hum Mutat 19:30-38.
6. Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT. 2010. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68:19-31.
7. Bi X, Liu J, Yao Y, Baudry M, Lynch G. 2005. Deregulation of the phosphatidylinositol-3 kinase signaling cascade is associated with neurodegeneration in Npc1-/- mouse brain. Am J Pathol 167:1081-1092.
8. Boot BP, Orr CF, Ahlskog JE, Ferman TJ, Roberts R, Pankratz VS, Dickson DW, Parisi J, Aakre JA, Geda YE, Knopman DS, Petersen RC, Boeve BF. 2013. Risk factors for dementia with Lewy bodies: A case-control study. Neurology 81:833-840.
9. Brecht WJ, Harris FM, Chang SJ, Tesseur I, Yu GQ, Xu Q, Fish JD, Wyss-Coray T, Buttini M, Mucke L, Mahley RW, Huang Y. 2004. Neuron-specific apolipoprotein E4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci 24:2527-2534.
10. Bu B, Li J, Davies P, Vincent I. 2002. Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J Neurosci 22:6515-6525.
11. Caceres LC, Bonacci GR, Sanchez MC, Chiabrando GA. 2010. Activated alpha(2) macroglobulin induces matrix metalloproteinase 9 expression by low-density lipoprotein receptor-related protein 1 through MAPK-ERK1/2 and NF-kappaB activation in macrophage-derived cell lines. J Cell Biochem 111:607-617.
12. Carnevale D, De Simone R, Minghetti L. 2007. Microglia-neuron interaction in inflammatory and degenerative diseases: Role of cholinergic and noradrenergic systems. CNS Neurol Disord Drug Targets 6:388-397.
13. Carstea ED, Morris JA, Coleman KG, Loftus SK, Zhang D, Cummings C, Gu J, Rosenfeld MA, Pavan WJ, Krizman DB, Nagle J, Polymeropoulos MH, Sturley SL, Ioannou YA, Higgins ME, Comly M, Cooney A, Brown A, Kaneski CR, Blanchette-Mackie EJ, Dwyer NK, Neufeld EB, Chang TY, Liscum L, Strauss JF III, Ohno K, Zeigler M, Carmi R, Sokol J, Markie D, O'neill RR, van Diggelen OP, Elleder M, Patterson MC, Brady RO, Vanier MT, Pentchev PG, Tagle DA. 1997. Niemann-Pick C1 disease gene: Homology to mediators of cholesterol homeostasis. Science 277:228-231.
14. Chen S, Averett NT, Manelli A, Ladu MJ, May W, Ard MD. 2005. Isoform-specific effects of apolipoprotein E on secretion of inflammatory mediators in adult rat microglia. J Alzheimers Dis 7:25-35.
15. Chua CC, Lim ML, Wong BS. 2010. Altered apolipoprotein E glycosylation is associated with A beta(42) accumulation in an animal model of Niemann-Pick Type C disease. J Neurochem 112:1619-1626.
16. Dawson HN, Cantillana V, Jansen M, Wang H, Vitek MP, Wilcock DM, Lynch JR, Laskowitz DT. 2010. Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease. Neuroscience 169:516-531.
17. Egensperger R, Kosel S, von Eitzen U, Graeber MB. 1998. Microglial activation in Alzheimer disease: Association with APOE genotype. Brain Pathol 8:439-447.
18. Forman MS, Trojanowski JQ, Lee VM. 2004. Neurodegenerative diseases: A decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 10:1055-1063.
19. Fu R, Yanjanin NM, Elrick MJ, Ware C, Lieberman AP, Porter FD. 2012. Apolipoprotein E genotype and neurological disease onset in Niemann-Pick disease, type C1. Am J Med Genet A 158A:2775-2780.
20. Gallardo G, Schluter OM, Sudhof TC. 2008. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. Nat Neurosci 11:301-308.
21. Gorovoy M, Gaultier A, Campana WM, Firestein GS, Gonias SL. 2010. Inflammatory mediators promote production of shed LRP1/CD91, which regulates cell signaling and cytokine expression by macrophages. J Leukocyte Biol 88:769-778.
22. Hallows JL, Iosif RE, Biasell RD, Vincent I. 2006. p35/p25 is not essential for tau and cytoskeletal pathology or neuronal loss in Niemann-Pick type C disease. J Neurosci 26:2738-2744.
23. Hauser PS, Ryan RO. 2013. Impact of apolipoprotein E on Alzheimer's disease. Curr Alzheimer Res 10:809-817.
24. Hovakimyan M, Maass F, Petersen J, Holzmann C, Witt M, Lukas J, Frech MJ, Hübner R, Rolfs A, Wree A. 2013. Combined therapy with cyclodextrin/allopregnanolone and miglustat improves motor but not cognitive functions in Niemann-Pick Type C1 mice. Neuroscience 252:201-211.
25. Huang Y. 2010. Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. Trends Mol Med 16:287-294.
26. Keene CD, Cudaback E, Li X, Montine KS, Montine TJ. 2011. Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease. Curr Opin Neurobiol 21:920-928.
27. Kim SJ, Lim MS, Kang SK, Lee YS, Kang KS. 2008. Impaired functions of neural stem cells by abnormal nitric oxide-mediated signaling in an in vitro model of Niemann-Pick type C disease. Cell Res 18:686-694.
28. Kodam A, Maulik M, Peake K, Amritraj A, Vetrivel KS, Thinakaran G, Vance JE, Kar S. 2010. Altered levels and distribution of amyloid precursor protein and its processing enzymes in Niemann-Pick type C1-deficient mouse brains. Glia 58:1267-1281.
29. Koffie RM, Hashimoto T, Tai HC, Kay KR, Serrano-Pozo A, Joyner D, Hou S, Kopeikina KJ, Frosch MP, Lee VM, Holtzman DM, Hyman BT, Spires-Jones TL. 2012. Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain 135:2155-2168.
30. Kohler C, Dinekov M, Gotz J. 2013. Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice. Neurobiol Aging 34:1369-1379.
31. Kuo YM, Crawford F, Mullan M, Kokjohn TA, Emmerling MR, Weller RO, Roher AE. 2000. Elevated A beta and apolipoprotein E in A betaPP transgenic mice and its relationship to amyloid accumulation in Alzheimer's disease. Mol Med 6:430-439.
32. Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, Hwang D, Masliah E, Lee SJ. 2010. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 285:9262-9272.
33. Li Y, Liu L, Barger SW, Griffin WS. 2003. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 23:1605-1611.
34. Liao G, Wen Z, Irizarry K, Huang Y, Mitsouras K, Darmani M, Leon T, Shi L, Bi X. 2010. Abnormal gene expression in cerebellum of Npc1-/- mice during postnatal development. Brain Res 1325:128-140.
35. Liao G, Yao Y, Liu J, Yu Z, Cheung S, Xie A, Liang X, Bi X. 2007. Cholesterol accumulation is associated with lysosomal dysfunction and autophagic stress in Npcl(-/-) mouse brain. Am J Pathol 171:962-975.
36. Loftus SK, Morris JA, Carstea ED, Gu JZ, Cummings C, Brown A, Ellison J, Ohno K, Rosenfeld MA, Tagle DA, Pentchev PG, Pavan WJ. 1997. Murine model of Niemann-Pick C disease: Mutation in a cholesterol homeostasis gene. Science 277:232-235.
37. Luo J, Wang H, Lin J, Redies C. 2007. Cadherin expression in the developing chicken cochlea. Dev Dyn 236:2331-2337.
38. Mahley RW, Weisgraber KH, Huang Y. 2006. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA 103:5644-5651.
39. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, Pfrieger FW. 2001. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294:1354-1357.
40. Minghetti L, Levi G. 1998. Microglia as effector cells in brain damage and repair: Focus on prostanoids and nitric oxide. Prog Neurobiol 54:99-125.
41. Morris JA, Zhang D, Coleman KG, Nagle J, Pentchev PG, Carstea ED. 1999. The genomic organization and polymorphism analysis of the human Niemann-Pick C1 gene. Biochem Biophys Res Commun 261:493-498.
42. Muratoglu SC, Mikhailenko I, Newton C, Migliorini M, Strickland DK. 2010. Low density lipoprotein receptor-related protein 1 (LRP1) forms a signaling complex with platelet-derived growth factor receptor-beta in endosomes and regulates activation of the MAPK pathway. J Biol Chem 285:14308-14317.
43. Naureckiene S, Sleat DE, Lackland H, Fensom A, Vanier MT, Wattiaux R, Jadot M, Lobel P. 2000. Identification of HE1 as the second gene of Niemann-Pick C disease. Science 290:2298-2301.
44. Ong WY, Kumar U, Switzer RC, Sidhu A, Suresh G, Hu CY, Patel SC. 2001. Neurodegeneration in Niemann-Pick type C disease mice. Exp Brain Res 141:218-231.
45. Osada N, Kosuge Y, Kihara T, Ishige K, Ito Y. 2009. Apolipoprotein E-deficient mice are more vulnerable to ER stress after transient forebrain ischemia. Neurochem Int 54:403-409.
46. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. 1999. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402:615-622.
47. Pressey SN, Smith DA, Wong AM, Platt FM, Cooper JD. 2012. Early glial activation, synaptic changes and axonal pathology in the thalamocortical system of Niemann-Pick type C1 mice. Neurobiol Dis 45:1086-1100.
48. Qin Q, Liao G, Baudry M, Bi X. 2010. Cholesterol perturbation in mice results in p53 degradation and axonal pathology through p38 MAPK and Mdm2 activation. PLoS One 5:e9999.
49. Rademakers R, Cruts M, van Broeckhoven C. 2004. The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum Mutat 24:277-295.
50. Raivich G, Bohatschek M, Kloss CU, Werner A, Jones LL, Kreutzberg GW. 1999. Neuroglial activation repertoire in the injured brain: Graded response, molecular mechanisms and cues to physiological function. Brain Res Brain Res Rev 30:77-105.
51. Richet E, Pooler AM, Rodriguez T, Novoselov SS, Schmidtke G, Groettrup M, Hanger DP, Cheetham ME, van der Spuy J. 2012. NUB1 modulation of GSK3beta reduces tau aggregation. Hum Mol Genet 21:5254-5267.
52. Saito Y, Suzuki K, Hulette CM, Murayama S. 2004. Aberrant phosphorylation of alpha-synuclein in human Niemann-Pick type C1 disease. J Neuropathol Exp Neurol 63:323-328.
53. Sawamura N, Gong JS, Garver WS, Heidenreich RA, Ninomiya H, Ohno K, Yanagisawa K, Michikawa M. 2001. Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice. J Biol Chem 276:10314-10319.
54. Schmued LC, Stowers CC, Scallet AC, Xu L. 2005. Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. Brain Res 1035:24-31.
55. Sheng JG, Jones RA, Zhou XQ, Mcginness JM, Van Eldik LJ, Mrak RE, Griffin WS. 2001. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: Potential significance for tau protein phosphorylation. Neurochem Int 39:341-348.
56. Smith D, Wallom KL, Williams IM, Jeyakumar M, Platt FM. 2009. Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1. Neurobiol Dis 36:242-251.
57. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. 2002. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 156:1051-1063.
58. Takikita S, Fukuda T, Mohri I, Yagi T, Suzuki K. 2004. Perturbed myelination process of premyelinating oligodendrocyte in Niemann-Pick type C mouse. J Neuropathol Exp Neurol 63:660-673.
59. Vantler M, Caglayan E, Zimmermann WH, Baumer AT, Rosenkranz S. 2005. Systematic evaluation of anti-apoptotic growth factor signaling in vascular smooth muscle cells - Only phosphatidylinositol 3 '-kinase is important. J Biol Chem 280:14168-14176.
60. Walkley SU, Baker HJ, Rattazzi MC, Haskins ME, Wu JY. 1991. Neuroaxonal dystrophy in neuronal storage disorders: Evidence for major GABAergic neuron involvement. J Neurol Sci 104:1-8.
61. Walkley SU, Suzuki K. 2004. Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim Biophys Acta 1685:48-62.
62. Wilhelmus MM, Bol JG, Van Haastert ES, Rozemuller AJ, Bu G, Drukarch B, Hoozemans JJ. 2011. Apolipoprotein E and LRP1 increase early in Parkinson's disease pathogenesis. Am J Pathol 179:2152-2156.
63. Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y. 2006. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci 26:4985-4994.
64. Yan X, Lukas J, Witt M, Wree A, Hubner R, Frech M, Kohling R, Rolfs A, Luo J. 2011. Decreased expression of myelin gene regulatory factor in Niemann-Pick type C 1 mouse. Metab Brain Dis 26:299-306.
65. Yu T, Lieberman AP. 2013. Npc1 acting in neurons and glia is essential for the formation and maintenance of CNS myelin. PLos Genet 9:e1003462.
66. Zervas M, Dobrenis K, Walkley SU. 2001. Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. J Neuropath Exp Neur 60:49-64.
67. Zhou L, Miller BL, Mcdaniel CH, Kelly L, Kim OJ, Miller CA. 1998. Frontotemporal dementia: Neuropil spheroids and presynaptic terminal degeneration. Ann Neurol 44:99-109.
68. Zhu Y, Nwabuisi-Heath E, Dumanis SB, Tai LM, Yu C, Rebeck GW, Ladu MJ. 2012. APOE genotype alters glial activation and loss of synaptic markers in mice. Glia 60:559-569.